Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide effect on metoprolol PK in healthy participants
NCT06808802Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retatrutide in obesity and Overweight, sponsored by Eli Lilly and Company. Primary endpoints: Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol at Day 3, Area Under Concentration From Time Zero to Infinity (AUC[0-∞]) of Metoprolol with Retatrutide at Day 11 and 2 more. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06808802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808802.